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Abstract
Phage display technology is one of the methods widely adopted for the production of human 
monoclonal antibodies. The subject of the present research was the scFv - single chain variable 
fragment antibody - which was able to recognize the D2-5-HT1A heteromer formed by dopamine D2 and 
serotonin 5-HT1A receptors. The antibody was selected using the phage display technique and the human 
antibody scFv phagemid library Tomlinson J. We investigated two expression systems: prokaryotic and 
eukaryotic. The results indicate that both of these systems (E.coli HB2151 and High Five cells (BTI-TN-
5B1-4) of Trichopulsia ni) are suitable for the production of scFv antibodies, but the scFvs obtained from 
insect cells could attain a higher protein concentration. Next, we examined a few purifi cation methods: 
immobilized-metal aﬃ  nity chromatography (IMAC), aﬃ  nity chromatography with the c-myc tag and the 
methods using protein L or A agarose, which are applicable to scFvs lacking tags. In the bacterial as well 
as insect cell expression systems, protein L agarose chromatography gave satisfactory results, and in 
our opinion, it is the best choice as a purifi cation resin. Additionally, circular dichroism measurements 
confi rmed the predominant content of secondary structures in the tested antibodies, which is consistent 
with the literature data.
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Introduction
ScFvs (single chain variable fragment) are small antibody 
fragments composed of immunoglobulin-heavy (VH) and 
light chain-variable (VL) regions with a fl exible peptide linker 
designed to connect the two chains such that the antigen 
binding site is retained in a single co-linear molecule [1]. 
Currently scFvs antibodies attract a lot of attention due to 
their potential usage in pharmacology and diagnostic fi elds 
[2-4]. The properties of this kind of antibodies make them 
an attractive modality for pharmaceutical development, 
especially in areas such as cancer and autoimmune diseases 
in which cell-cell interactions or ligand-receptor interactions 
play a crucial role in the pathogenesis [5]. Moreover, scFvs are 
very useful nanoprobes for the targeted delivery of drugs to 
specifi c cells or tissues since they can be successfully used as 
targeting ligands for the functionalization of nanocarriers [6]. 
In comparison to the much larger Fab, F(ab)2, and IgG forms 
of the monoclonal antibodies from which they are derived, 
scFvs have lower retention times in non-target tissues, more 
rapid blood clearance, better tissue penetration and reduced 
immunogenicity, making them attractive for therapeutic 
applications [7]. 
ScFvs antibodies can be derived from phage display libraries 
[8,9]. Phage display technology (based on the signifi cant work 
of Smith, 1985) [10] is an in vitro screening technique that 
allows rapid selection of multiple monoclonal antibodies of high 
affi nity and specifi city [11]. The nature of the method enables 
the rapid and effi cient identifi cation of specifi c binders, as well 
as greater control over the selection parameters that facilitate 
the isolation of antibodies with unique, desirable functional 
characteristics [5].
Very often, scFvs contain poly-His or/and c-myc tags that 
are used in their purifi cation and identifi cation in vitro. Many 
protocols describe scFv production and purifi cation in specifi c 
expression systems, including bacteria, yeast, plant, insect, 
and mammalian cells, as well as in transgenic animals [12-15]. 
Depending on the expression system, their ability to fold and 
secrete the scFv proteins varies [16].
In this report, we investigated two expression systems: 
prokaryotic and eukaryotic. We present the results from 
the preparation of scFv expressed in E.coli HB2151 and High 
Five cells (BTI-TN-5B1-4) of Trichopulsia ni. Prokaryotic 
expression systems have several advantages including low 
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cost of production and the ability to produce large amounts 
of recombinant proteins in short periods of time, but their 
main drawback is the accumulation of aggregated material 
in the cytoplasm, known as inclusion bodies. On the other 
hand, a signifi cant advantage of insect cells is their capability 
to perform most posttranslational modifi cations used by 
higher eukaryotes, such as glycosylation, phosphorylation, 
acylation and palmitylation [17]. In the present work, we 
focused on developing a simple, fast and effi cient method 
for the purifi cation of soluble scFv fragments. We examined 
a few purifi cation methods: immobilized-metal affi nity 
chromatography (IMAC), which is only applicable to scFvs 
containing a poly His-tag; affi nity chromatography with the 
c-myc tag; and the methods using protein L or A agarose, 
which are applicable to scFvs lacking tags. The subject of the 
research was scFvs antibodies specifi cally recognizing D2-5-
HT1A heteromer (dimer formed by dopamine D2 and serotonin 
5-HT1A receptors) selected using the phage display technique 
and the human antibody scFv phagemid library Tomlinson J. 
The presented results have been collected for at least several 
various scFv proteins whose common characteristic was 
selectivity against D2-5-HT1A membrane proteins. Although 
we described data only for different types of scFvs antibodies 
selective for one type of heteromer, the presented results were 
similar also for other types of scFvs antibodies obtained against 
other various membrane receptors (data not shown). We 
choose scFvs against D2-5-HT1A heteromer for publication as 
a representative case since it would be diffi cult to show results 
for all proteins which were obtained in our lab and it would 
make the work unreadable and confusing. Bearing in mind 
diffi culties in obtaining scFv specifi cally recognizing dimers of 
membrane receptors the statistical attempt and data collected 
in the presented work seem to be interesting and may be a good 
starting point in designing similar experiments.
Materials and Methods
Selection of human monoclonal scFv antibody
Human monoclonal scFvs antibodies were selected using 
the phage displayed library Tomilson J (Geneservise) which was 
amplifi ed and titrated according to the manufacturer’s protocols 
using E. coli TG1 cells. In total, 1.9x1013 individual clones were 
panned and screened against D2-5-HT1A heteromers presented 
on the surface of CHO-K1 cells stably expressing both desired 
receptors. Five rounds of positive selection followed by negative 
preselection (where CHO-K1 cells expressing D2R mixed with 
CHO-K1 cells expressing 5-HT1AR (1:1) (CHO-negative cells; 
CHO-) were used) and fi nally 2 negative selections were 
performed. Before protein expression, the cDNAs of scFvs from 
the selected phages were isolated and sequenced to check for 
the presence of STOP codons inside the coding sequence. 
Prokaryotic expression system
To obtain soluble scFv expressed in E. coli, HB2151 (Novagen) 
cells were transformed with selected vector plasmids. A single 
colony was used to inoculate 5 ml of 2xYT medium+Amp (100 
μg/ml) (Lab Empire), and the cultures were grown overnight 
at 37°C. A 0.5 ml portion of the overnight culture was used 
to inoculate 25 ml of medium, and then this culture was 
used to start a 1L culture at 37°C. Expression was induced in 
the host bacteria by adding IPTG (Sigma-Aldrich) to a fi nal 
concentration of 1 mM when the OD600 reached 0.9. Cells were 
cultured for 16 h at 28°C, and then the cells were harvested by 
centrifugation (4000 g, 15 min, 4°C). The cells were placed on 
ice until the purifi cation of scFv procedure was started.
Eukaryotic expression system 
The production of scFv in eukaryotic cells was conducted 
with the Bac-to-Bac Baculovirus Expression System from 
Invitrogen (Thermo Fisher Scientifi c). Sf9 and High Five cells 
were cultured in ESF 921 Insect Cell Culture Medium from 
Expression Systems supplemented with antibiotic-antimycotic 
solution (Sigma-Aldrich). Cells were maintained and expanded 
at 28°C without CO2 as monolayer cultures in tissue culture 
bottles or as suspension cultures in Erlenmeyer shake fl asks. 
The cDNAs of the selected scFv antibodies were cloned 
using EcoRI and HindIII into the pFastBac1 vector (Bac-to-Bac 
Baculovirus Expression System, Invitrogen). Double digestion 
with the same restriction enzymes was used to confi rm the 
correct cDNA subcloning. Recombinant bacmids were generated 
by Tnt transposition into DH10Bac E. coli cells (Invitrogen). In 
this procedure, 1 mg of the donor plasmids (pFastBac) containing 
the scFv antibody cDNAs was used for transformation into the 
DH10Bac cells. The transformed DH10Bac bacteria were grown 
for 48 h at 37°C on selective LB agar plates containing 7 mg/
ml gentamicin, 10 mg/ml tetracycline, 50 mg/ml kanamycin, 
100 mg/ml Bluo-gal and 40 mg/ml IPTG. Recombinant bacmid 
DNAs were extracted from white single colonies obtained in 
a blue-white test. Transposition of the scFv cDNA into the 
bacmid DNA was confi rmed with PCR. Positively verifi ed 
recombinant bacmids were used for baculovirus production. 
Sf9 cells were transfected with 3 μg of recombinant bacmids 
using Cellfectin-II (Invitrogen). Transfected cells were allowed 
to grow in a monolayer culture and were observed daily for 
signs of viral infection and cytopathic effects. At 72 hours after 
transfection, baculoviruses were harvested (200 g, 10 min, 
4°C), and baculovirus infectious titers were determined in a 
viral plaque assay. Baculoviruses were amplifi ed in Sf9 cells 
and then used to infect High Five cells with a multiplicity of 
infection 5. Cells were harvested 48 hours after infection (200 
g, 10 min, 4°C) and stored at -80°C until the purifi cation steps.
Expression level analysis
After scFv expression obtained periplasmatic fraction 
from E.coli HB2151 as well as cell lisates from High Five cells 
were analysed by ELISA technique using affi nity of the scFv 
(Tomilson J) fragments to protein A. Protein A resuspended in 
PBS buffer (1 μg/ml) was added to each well of 96-well plate 
(50 μl per well) and incubated overnight at 4°C. Then the plate 
was blocked using 2 % BSA solution (1 h, 37°C) and 50 μl of 
investigated samples (periplasmatic fraction or cell lysates) 
were added to appropriate wells and incubated at 37°C for 1 h. 
The washing step was conducted 3 times 200 ml PBS. Then 50 
ml of protein L conjugated with HRP (protein L was resuspended 
in 0.5% BSA/PBS at a 1:2000 ratio) (GE Healthcare) was added 
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to the wells and incubated for 30 min at 37°C. After washing 
(carried out 4 times as described above), the reactions were 
developed by TMB substrate (GE Healthcare). Experiments 
were performed in triplicate. 
scFv purifi cation
ScFvs derived from E.coli and insect cells were purifi ed at 
room temperature, but the buffers used were ice-cold.
Bacterial expression system: ScFvs are secreted into the 
periplasmic space located between the outer and inner 
membranes of bacteria. The pellet of bacterial cells was 
resuspended in buffer consisting of 50 mM Tris-HCl, 20% 
sucrose, pH 8.0, 1 mM EDTA, and 1x Protease Inhibitor Cocktail 
(20 ml buffer/1L overnight culture). The cells were incubated 
on ice for 15 min with gentle agitation, then the cell suspension 
was centrifuged at 30000 g for 30 min at 4°C. The supernatant 
was the osmotic shock fl uid containing periplasmic proteins 
and was divided into two equal parts. One part was dialyzed 
extensively against Protein L Binding Buffer (100 NaH2PO4, pH 
7.2; 150 mM NaCl), and the second part against IMAC Binding 
Buffer (50 mM NaH2PO4 pH 8.0, 500 mM NaCl, 15% glycerol, and 
0.05% Tween 20). The dialysis was carried out at 4°C overnight 
before continuing with the purifi cation. The supernatant was 
centrifuged after dialysis (30000 g, 30 min, 4°C).
Ni-NTA Agarose: The clear supernatant was collected and 
applied to immobilized-metal affi nity chromatography (IMAC) 
with a 5 ml Ni-NTA Agarose (Qiagen) column equilibrated 
with IMAC Binding Buffer. The column was then washed 
sequentially with IMAC Washing Buffer (50 mM NaH2PO4 pH 
8.0, 500 mM NaCl, 15% glycerol, 0.05% Tween 20, and 20 mM 
imidazole) and IMAC Elution Buffer (50 mM NaH2PO4 pH 8.0, 
500 mM NaCl, 15% glycerol, 0.05% Tween 20, and 300 mM 
imidazole). The fl ow rate during application, washing and 
elution was 1.0 ml/min. The purifi cation of scFv was examined 
by running an aliquot of the collected samples on SDS-PAGE 
and then staining with Coomassie Brilliant Blue. The purifi ed 
proteins were pooled and dialyzed against 1xPBS at 4°C 
overnight. The proteins were kept at -80°C after determination 
of the concentration by a Bradford assay.
Protein L Agarose: The extract of E.coli scFvs was loaded onto 
a column fi lled with 5 ml of protein L agarose (Thermo Fisher 
Scientifi c) equilibrated with Protein L Binding Buffer at a fl ow 
rate of 1.0 ml/min. After washing with 10 column volumes of 
binding buffer, the proteins were eluted from the column with 
elution buffer that contained 0.1 M glycine at pH 2.5 (at a fl ow 
rate of 1.0 ml/min). Immediately, the eluted fractions were 
adjusted to physiological pH by adding 100 μL of neutralization 
buffer (1 M Tris, pH 8.0) to 1 ml of eluate. Fractions containing 
scFvs (as judged by SDS-PAGE and Coomassie Brilliant Blue 
staining) were pooled and dialyzed against 1xPBS at 4°C 
overnight. The concentration of protein was calculated by a 
Bradford assay. The purifi ed fractions were stored at -80°C.
Protino Ni-IDA 1000: A clear mixture of proteins from the 
periplasm of E.coli was dialyzed against the 1x LEW buffer 
(Lysis-Equlibration-Wash Buffer, 50 mM NaH2PO4 pH 8.0, 
300 mM NaCl.) Onto the equilibrated column (with 1xLEW 
buffer) fi lled with Ni-IDA 1000 (Macherey-Nagel), a fraction 
of periplasmic protein was applied (at fl ow rate 1.0 ml/min). 
Subsequently, the weakly bound proteins were washed away 
(1xLEW buffer, 5 x column volume, fl ow rate 1.5 ml/min), and 
elution was performed using a mixture of 1xLEW + 10 mM 
imidazole buffer and 1xLEW + 250 mM imidazole buffer with an 
imidazole gradient (up to 250 mM imidazole) (at a fl ow rate of 
1.5 ml/min). From the fractions obtained after elution, samples 
for SDS-PAGE were prepared. The protein concentration was 
determined using the Bradford method. The fractions in which 
the presence of protein was found were dialyzed against 1xPBS 
and frozen at -80°C.
Protein A Antibody Purifi cation:  A sample containing proteins 
from the periplasmic fraction was diluted 2 x with binding 
buffer (included in the purifi cation kit). The purifi cation 
procedure was carried out according to the protocol provided 
by the manufacturer (Sigma-Aldrich).
Insect cells expression system: High Five cells were lysed 
by lysis buffer (50 mM Tris pH 7.5, 10% glycerol, 1% Triton 
X-100, 150 mM NaCl, 10 mM MgCl2, and 1 x Protease Inhibitor 
Cocktail) and shaken for 10 min in an ice bath. After lysis, the 
cell suspension was centrifuged (30000 g, 30 min, 4°C). The 
purifi cation procedures for scFvs from insect cells with Ni-
NTA Agarose, Protino Ni-IDA 1000 and Protein L Agarose were 
carried out in the same manner as previously described for 
bacterial scFvs.
Purifi cation of insect antibodies with the c-myc tag: The 
cultures of High Five or Sf9 insect cell clones were thawed on 
ice. The pellet was suspended in lysis buffer (50 mM NaH2PO4, 
500 mM NaCl, 15% glycerol, and 0.05% Tween 20 at pH 8.0 
with the addition of 1 x protease inhibitors) and incubated 
on ice for 15 min. The sample was then centrifuged (30000 
g, 10 min, 4°C), and the supernatant was transferred to a 
spin-column containing Pierce™ Anti-c-Myc Agarose and 
incubated for 2.5 hours with gentle stirring in a cold room. 
After incubation, the sample was centrifuged (14000 g, 10 
s, RT). The spin columns were rinsed 3x times with TBS-T 
buffer (25 mM Tris, 0.15 M NaCl, pH 7.2 + 0.05% Tween) and 
1x conditioning buffer (Thermo Fisher Scientifi c). The elution 
was carried out using two methods: (a). with Elution Buffer pH 
2 (Thermo Fisher Scientifi c) and centrifugation (14 000 g, 10 s, 
RT), repeated 3 times in total, followed by addition of 1 M Tris 
pH 9.5 to the sample with elution buffer; and (b). By addition to 
a spin column with 25 μL Lane Marker Non-Reducing Sample 
Buffer 2x (prepared from 5x concentrate, Thermo Fisher 
Scientifi c), mixing and incubation for 5 min at 99°C, followed 
by centrifugation (14 000 g, 10 s, RT).
SDS-PAGE and Western blotting: Samples for analysis were 
mixed with 2x electrophoresis buffer containing 50 mM Tris-
HCl at pH 6.8, 10% glycerol, 2% SDS, 0.1% bromophenol blue 
and 5% -mercaptoethanol and heated for 5 min at 95°C. SDS-
PAGE was performed according to Laemmli (1970) [18], with a 
4% stacking gel and a 12% resolving gel (Mini-Protean 3, Bio-
Rad). Gels were stained by Coomassie Brilliant Blue.
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In the immunodetection identifi cation experiment, protein 
bands from the SDS-PAGE gel were transferred to a PVDF 
membrane immediately after separation. Electrotransfer was 
performed in ice cold buffer (25 mM Tris-HCl at pH 8.3, 192 
mM glycine, and 20% (v:v) methanol) at 100 V for 1 h. The 
PVDF membrane was then blocked in TBST buffer (20 mM 
Tris, pH 7.5, 150 mM NaCl, and 0.1% Tween 20) with 5% w/v 
non-fat dry milk for 1 h at room temperature. Afterward, the 
membrane was washed with TBST buffer three times for 10 
min and incubated with Anti-c-Myc primary antibody (Sigma 
C3956) in blocking buffer overnight at 4°C on a shaker. The 
membrane was washed with TBST three times for 10 min at 
room temperature, and secondary antibody (Santa Cruz, sc-
2030) in blocking buffer was added for 1 h. Then, the membrane 
was washed with TBST three times for 10 min. Finally, the 
membrane was incubated with Santa Cruz Biotechnology 
Luminol reagent for 1 min and visualized using Fusion FX5/
quantum system (Vilber Lourmat).
Analysis of the specifi city of the obtained scFvs mono-
clonal antibodies
The specifi city of the purifi ed scFvs was determined 
by ELISA. One hundred ml aliquots of purifi ed antibodies 
at different concentrations resuspended in 4% BSA were 
incubated for 1.5 h at 37°C in 96-V-well plate. Then, 1.5 x105 
CHO+ cells (expressing D2-5-HT1A heteromers) as well as CHO- 
cells (expressing D2R, 5-HT1AR) or CHO-K1 cells (resuspended 
in 50 ml of RPMI with 5% FBS) (Sigma-Aldrich) were added to 
the appropriate wells and incubated on ice for 1 h. The washing 
step was conducted 3 times at 4°C using 200 ml cold PBS, and 
after each round, the cells were centrifuged (300 g, 10 min, 
4°C) and the supernatant was aspirated off. Then, the pellets 
were resuspended in 50 ml protein L conjugated with HRP 
(protein L was resuspended in 0.5% BSA/PBS at a 1:2000 ratio) 
(GE Healthcare) and incubated for 30 min on ice. After washing 
(carried out 4 times as described above), the reactions were 
developed by TMB substrate (GE Healthcare). Experiments 
were performed in triplicate. 
Circular dichroism measurements (CD Measurements)
Circular dichroism (CD) spectra were measured with a JASCO 
710 spectropolarimeter at 20°C in a 0.1 cm cuvette. The spectra 
were run from 190 to 250 nm. Each spectrum was recorded at 
least three times and averaged. The fi nal concentrations of the 
antibodies were 0.2 mg/mL in 1xPBS and protein stabilizing 
cocktail, which helps extend the shelf-life of most proteins. 
CD measurements were aimed at determining the content of 
secondary structures in the tested antibodies and investigating 
their stability.
Results and Discussion
Phage display technology is a very useful tool for the isolation 
of target-specifi c monoclonal antibodies. Unfortunately, 
the relatively fast selection process does not always coincide 
with the fast expression and purifi cation of the protein. There 
are a number of different strategies (such as bacterial cells 
[19,20], mammalian cells [21], yeast [22], plant cells [23], and 
insect cells [24]) used to express scFv antibody fragments. 
The proteins can be expressed as correctly folded and directly 
active proteins or as aggregates requiring in vitro refolding 
to become active [16]. There are some general regulations to 
consider in the design of vectors and expression systems used 
with the different hosts, and each of the hosts has advantages 
and disadvantages for the production of active scFv antibodies 
[17,25]. Additionally, a wide range of methodologies has been 
adapted for successful purifi cation of the given protein [17]. 
Nevertheless, success depends to a large extent on the properties 
of the antibody itself, which we are not able to predict in the 
early stages of selection. A problem that often accompanies the 
preparation of antibodies is their instability. Because of the 
nature of scFv fragments, this kind of antibody is less stable 
than the whole antibody. For example, immunoglobulin G 
(IgG) is a heterotetrameric molecule consisting of two heavy 
and two light chains connected via disulfi de bonds. Heavy and 
light chains (HC and LC) also contain intramolecular disulfi de 
bonds for stabilization [26]. In comparison, scFv consists only 
of variable (V) regions, and it possesses a soluble and fl exible 
amino acid peptide linker which connects the V regions [7] and 
one disulfi de bond for stabilization. 
Because of the problems mentioned above, in the present 
work, we focused on the comparison of some strategies used 
to produce and purify soluble scFv antibodies. Two different 
expression systems - bacterial and insect cells - were adopted 
for this purpose. In both cases, (E.coli and insect cells), scFvs 
antibodies were successfully obtained (Figure 1).
Figure 1: Expression level of various anti-D2-5-HT1A scFvs antibodies as shown by 
ELISA using aﬃ  nity to protein A, positive control – scFv anti-BSA, negative control 
– isolation buffer; A) expression of different proteins of scFvs antibodies in E.coli 
HB2151, 1F2, 7F, 10G, 1G, 1C, 4H, 6F – sample code refl ects various, individual 
proteins; B) 1G_scFv expression in insect cells (High Five) – dependence of the 
scFv expression level on various MOI (multiplicity of infection), representative 
results.
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There are three locations from which bacterially expressed 
proteins can be isolated: the cytoplasm, the periplasm, and the 
culture supernatant. Many studies showed that the majority 
of proteins are expressed as insoluble inclusion bodies in the 
cytoplasm of E.coli [27,28]. The purifi cation of inclusion bodies 
is often interconnected with denaturation and refolding, 
which is problematic as far as the production of active soluble 
scFv antibodies is concerned [16]. In this study, soluble scFv 
antibodies were expressed in non-suppressive E. coli HB2151 
bacteria cells. There is a termination codon between the phage 
pIII gene and the scFv gene. When the phage infects non-
suppressive E. coli HB2151 cells, the termination codon will be 
translated. Therefore, the scFv gene will not be expressed as a 
fusion protein with pIII in HB2151 cells, but it will be expressed 
as the soluble protein and secreted into the periplasmic zone. 
In the E. coli expression system, the periplasmic compartment 
is preferably used for recombinant protein production. There 
appears to be much less protease activity in the periplasmic 
space than in the cytoplasm. In addition, scFv antibodies 
purifi cation is simpler due to fewer contaminating proteins in 
the periplasm. Another advantage is that the correct formation 
of disulfi de bonds can be facilitated in this location because 
the periplasmic space provides a more oxidative environment 
than does the cytoplasm, and it is rich in proteins which are 
important for folding and catalysing disulfi de bond formation 
(PDI, DsbA and DsbC) or chaperones [29,30].
On the other hand, the use of a baculovirus expression 
system is a promising way to produce molecules for therapeutic 
purposes because of its capability of posttranslational 
modifi cations and absence of molecules toxic to humans, since 
the baculoviruses have a highly restricted host range. This was 
the fi rst system that linked the advantages of bacterial systems, 
such as high production levels and scalability, with protein 
processing typically used in eukaryotic cells. Furthermore, 
insect cells can be grown on serum-free media, which is an 
advantage in terms of biosafety as well as cost. Increasing 
understanding of insect cell biology has led to technological 
advances in baculovirus production strategies over the last 
30 years. One of the milestones that led to simplifi cation 
and indefectibility was the deletion of an essential gene and 
insertion of the bacterial origin of replication into the viral 
genome, along with subsequent development of the E. coli 
DH10Bac strain containing the baculovirus genome as a part of 
the bacmid and a helper plasmid carrying a transposase gene. 
Transfection of these cells with transfer plasmids containing 
genes of interest controlled by polyhedrin promoter, fl anked by 
sequences recognized by the transposase, causes transposition 
of the gene of interest into the polyhedrin locus of the bacmid, 
which contains matching Tn7 sequences. As a result of 
this process, the lacZ gene is deleted from the bacmid DNA, 
which enables one to use blue-white screening to isolate the 
recombinant bacmid DNA [31]. This kind of in vivo transposition 
guaranties 100% effi ciency in producing recombinant 
baculovirus DNA, and this approach, known as the Bac-to-Bas 
system, was used in this study. A baculovirus carrying cDNA 
of scFV antibody was created and amplifi ed in Sf9 cells. The 
high-titer baculovirus was used to infect High Five cells, which 
are considered to be more effi cient at producing recombinant 
antibodies than Sf9 cells [32]. In preliminary experiments, 
both the multiplicity of infection and the time of cell growth 
after infection were tested. These optimization steps showed 
that satisfactory scFv production was achieved when the MOI 
(multiplicity of infection) amounted to 5 and cells were grown 
for 48 hours after infection. In conclusion, this stage of the 
studies showed that both investigated expression systems are 
suitable for scFv production. 
In the next step, we compared a few methods of the 
purifi cation of scFvs expressed as soluble proteins in E. coli 
and insect cells using affi nity chromatography. Application 
of different methodologies available for antibody purifi cation 
is widespread, as underlined in some thematic papers, 
e.g. [33–35]. Protein L agarose purifi cation is a one-step 
purifi cation method that yields signifi cant amounts of pure 
protein. Protein L is an immunoglobulin-binding protein that 
was isolated from the bacteria Peptostreptococcus magnus and 
is now produced as a recombinant protein. Protein L binds 
to scFv without interfering with the antigen binding site. 
However, problems may occur during protein elution because 
the process requires very low-pH buffer (in our case, pH 2), 
which may have an adverse impact on protein stability. Protein 
A is a cell wall component produced by several strains of 
Staphylococcus aureus. The 46.7-kDa protein consists of a single 
polypeptide chain that is essentially devoid of carbohydrates. 
Native protein A contains four high-affi nity binding sites (Ka 
= 108/mol) that are capable of interacting with the Fc region 
of IgG-class antibodies from selected mammalian species. 
The IgG-binding function is optimal at pH 8.2, but effi cient 
binding also occurs in neutral and physiological buffers (pH 
7.0 to 7.6). The IMAC with Ni-NTA Agarose and Protino Ni-
IDA 1000 requires the presence of a His tag for effi cient protein 
purifi cation. Based on theoretical assumptions, all techniques 
mentioned above should yield positive effects, and pure, 
soluble protein should be obtained. Unfortunately, despite 
good validation, not all techniques gave satisfactory results. A 
fraction containing purifi ed scFvs was not obtained with the 
immobilized-A protein beads. Similar results were obtained 
in the case of IMAC methodology—the purifi ed antibody was 
obtained at very low concentrations. Only the purifi cation of 
scFv antibodies by affi nity chromatography with the L protein 
gave positive results, and highly concentrated protein samples 
were obtained (Figure 2). 
Figure 2: SDS-PAGE electrophoresis – analysis of various anti-D2-5-HT1A scFvs 
antibodies purifi ed by aﬃ  nity chromatography with the L protein, representative 
results, A) 1G_scFv expressed in E.coli HB2151, B) 1G_scFv expressed in High Five 
insect cells; C) Purifi ed anti-D2-5-HT1A scFvs antibodies, 1F2, 7F, 10G, 1G, 1C, 4H, 
6F – sample code refl ects various, individual proteins.
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Additionally, the purifi cation results were confi rmed by 
Western blot analysis (Figure 3).
Moreover, following scFv expression in insect cells, 
attempts to purify antibodies with an attached c-myc tag were 
undertaken, but unfortunately, yielded no success. Therefore, 
the results indicate that the purifi cation of scFv antibodies only 
by affi nity chromatography with L protein gave satisfactory 
results.
Additionally, CD measurements confi rmed the predominant 
content of secondary structures in the tested antibodies (Figure 
4), which was consistent with the literature data [36]. 
The analysis of specifi city of the obtained scFvs monoclonal 
antibodies showed positive results (Figure 5). The antibodies 
with increased affi nity to the given heteromer were obtained.
The major problem that occurred during the experiments 
was connected with the maintenance of protein stability, 
especially during prolonged storage. To overcome this 
problem, protein stabilizing cocktail was added to the purifi ed 
antibodies. It has been widely accepted that solutions of 
enzymes and other proteins to which the cocktail is added 
may be refrigerated or frozen for storage without losing their 
activity or function. Unfortunately, this method did not work 
satisfactorily in our case. 
Conclusion
The speed, along with the in vitro nature of the selection 
process and the ability to produce human antibodies, makes 
phage display a very potent technology for the generation of 
scFvs antibodies suitable for therapeutic development [5]. 
However, despite the numerous benefi ts of the methods, 
problems associated with obtaining soluble and active forms 
of proteins often arise. Therefore, in the present work, we 
compared prokaryotic and eukaryotic expression systems for 
the production of soluble scFv antibodies. Both systems are 
useful tools. In both the bacterial and insect cell expression 
systems, protein L agarose chromatography gave satisfactory 
results, and in our opinion, it is the best choice as a purifi cation 
resin. 
Acknowledgments
The manuscript has been corrected by AJE - Certifi cate 
Verifi cation Key 414B-1A48-2CC6-B7D2-09D2. The Faculty 
of Biochemistry, Biophysics and Biotechnology is partner with 
the Leading National Research Centre (KNOW) supported by 
the Ministry of Science and Higher Education. This work was 
supported by grants 35+ Nr. 35p/1/2016 from KNOW. 
References
1. Bird RE, Hardman KD, Jacobson JW, Johnson S, Kaufman BM, et al. (1998) 
Single- chain antigen-binding proteins. Science 242: 423–426. Link: 
https://tinyurl.com/y6tphe7f 
2. Schwimmer LJ, Huang B, Giang H, Cotter RL, Chemla-Vogel DS, et al. 
(2013) Discovery of diverse and functional antibodies from large human 
repertoire antibody libraries. J Immunol Methods 391: 60-71. Link: 
https://tinyurl.com/yy27p2ln 
3. Chan CE, Chan AH, Lim AP, Hanson BJ (2011) Comparison of the eﬃ  ciency 
of antibody selection from semi-synthetic scFv and non-immune Fab 
phage display libraries against protein targets for rapid development 
of diagnostic immunoassays. J Immunol Methods 373: 79-88. Link: 
https://tinyurl.com/y6os97qd 
4. Hoen PA, Jirka SM, Ten Broeke BR, Schultes EA, Aguilera B, et al. (2012) 
Phage display screening without repetitious selection rounds. Anal Biochem 
421: 622-631. Link: https://tinyurl.com/y3f7pufz
5. Shim H (2017) Antibody Phage Display, Springer International Publishing AG. 
Springer Nature.
6. Tanabe A, Nakano K, Nakakido M, Nagatoishi S, Tanaka Y, et al. (2018) 
Production and characterization of a novel site-specifi c-modifi able anti-OX40-
receptor single-chain variable fragment for targeted drug delivery. Biochem 
Biophys Res Commun 496: 614-620. Link: https://tinyurl.com/y4gvopsh 
Figure 3: Western blot analysis (with anti-c-myc primary antibody) of purifi ed anti-
D2-5-HT1A 1G_scFv antibody. Representative result.
Figure 4: CD assay for 1G_scFv monoclonal antibody specifi c to D2-5-HT1A 
heteromer.
Figure 5: Analysis of the D2-5-HT1A heteromer specifi city of the obtained various 
scFvs monoclonal antibodies determined by ELISA technique. 1F2, 7F, 10G, 1G, 1C, 
4H, 6F – sample code; refl ects various, individual proteins [W] – ratio of positive 
vs negative signal. Positive signal - the absorbance (450nm) acquired for positive 
cells (CHO+ expressing D2-5HT1A heteromers), negative signal – the absorbance 
(450 nm) acquired for negative cells (CHO expressing 5-HT1AR, D2R, or CHO 
without expression of mentioned above receptors, respectively).
020
Publications Pvt. Ltd.
Citation: Łukasiewicz S, Stachowicz A, Fic E, Błasiak E, Kowalik A, et al. (2019) Different Strategies used in the Production of human monoclonal scfv Antibodies 
Specific to Dimers of Membrane Receptors. J Biol Med 3(1): 014-020. DOI: http://dx.doi.org/10.17352/jbm.000007
Copyright: © 2019 Mobolade AJ, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted 
use, distribution, and r eproduction in any medium, provided the original author and source are credited.
7. Frenzel A, Hust M, Schirrmann T (2013) Expression of recombinant 
antibodies. Front Immunol 4: 217. Link: https://tinyurl.com/y2gazcad 
8. Barbas CF (2001) Phage display: a laboratory manual, Cold Spring Harbor, 
NY. Cold Spring Harbor Laboratory Press. Link: https://tinyurl.com/yyx9gaev 
9. Lee CM, Iorno N, SierroF, Christ D (2007) Selection of human antibody 
fragments by phage display. Nat Protoc 2: 3001–3008. Link: 
https://tinyurl.com/y57yn2et 
10. Smith GP (1985) Filamentous fusion phage: novel expression vectors that 
display cloned antigens on the virion surface. Science 228: 1315-1317. Link: 
https://tinyurl.com/y6sp6tqp 
11. Hoogenboom HR (2005) Selecting and screening recombinant antibody 
libraries. Nat Biotechnol 23: 1105-1116. Link: https://tinyurl.com/y5t2ghzq 
12. Miller KD, Weaver-Feldhaus J, Gray SA, Siegel RW, Feldhaus MJ (2005) 
Production, purifi cation, and characterization of human scFv antibodies 
expressed in Saccharomyces cerevisiae, Pichia pastoris, and Escherichia 
coli. Protein Expr Purif 42: 255-267. Link: https://tinyurl.com/y3x58s6v 
13. Jefferis R (2009) Recombinant antibody therapeutics: the impact of 
glycosylation on mechanisms of action. Trends Pharmacol Sci 30: 356-362. 
Link: https://tinyurl.com/y4avxwlf 
14. Sakamoto S, Taura F, Tsuchihashi R, Putalun W, Kinjo J, et al. (2010) 
Expression, purifi cation, and characterization of anti-plumbagin single-chain 
variable fragment antibody in Sf9 insect cell. Hybridoma 29: 481-488. Link: 
https://tinyurl.com/y32at9fd 
15. Wang Y, Zhang X, Zhang C, Liu Y, Liu X (2012) Isolation of single chain 
variable fragment (scFv) specifi c for Cry1C toxin from human single. Toxicon 
60: 1290-1297. Link: https://tinyurl.com/y6kdq826 
16. Ahmad ZA, Yeap SK, Ali AM, Ho WY, Alitheen NB, et al. (2012) scFv antibody: 
principles and clinical application. Clin Dev Immunol 2012: 980250. Link: 
https://tinyurl.com/y2m7hgzv 
17. Verma R, Boleti E, George AJ (1998) Antibody engineering: comparison of 
bacterial, yeast, insect and mammalian expression systems. J Immunol 
Methods 216: 165-181. Link: https://tinyurl.com/y6bxen9z 
18. Laemmli UK (1970) Cleavage of structural proteins during the 
assembly of the head of bacteriophage T4. Nature 227: 680–685. Link: 
https://tinyurl.com/yxwelzxs 
19. Skerra A, Plückthun A (1988) Assembly of a functional immunoglobulin 
Fv fragment in Escherichia coli. Science 240: 1038–1041. Link: 
https://tinyurl.com/yyah8npt 
20. Mergulhão FJM, Monteiro GA, Cabral JMS, Taipa MA (2004) Design 
of bacterial vector systems for the production of recombinant 
proteins in Escherichia coli. J Micro and Biotech 14: 1–14. Link: 
https://tinyurl.com/y39gdq2c 
21. Ho M, Nagata S, Pastan I (2006) Isolation of anti-CD22 Fv with high 
aﬃ  nity by Fv display on human cells. PNAS 103: 9637–9642. Link: 
https://tinyurl.com/yyh86ejg 
22. Wang Y, Shan Y, Gao X, Gong R, Zheng J, et al. (2018) Screening and 
expressing HIV-1 specifi c antibody fragments in Saccharomyces cerevisiae. 
Mol Immunol 103 279-285. Link: https://tinyurl.com/yxn52xg3 
23. Galeﬃ   P, Lombardi A, Pietraforte I, Novelli F, Di Donato M, et al. 
(2006) Giacomini, Functional expression of a single-chain antibody 
to ErbB-2 in plants and cell-free systems. J Transl Med 4: 39. Link: 
https://tinyurl.com/y64gqn7v 
24. Choo ABH, Dunn RD, Broady KW, Raison RL (2002) Soluble expression of a 
functional recombinan cytolytic immunotoxin in insect cells. Prot Expres and 
Purifi c 24: 338–347. Link: https://tinyurl.com/y2dwdubc 
25. Knaust RKC, Nordlund P (2001) Screening for soluble expression of 
recombinant proteins in a 96-well format. Analyt Biochem 297: 79–85. Link: 
https://tinyurl.com/y43b5xqw 
26. Edelman GM (1973) Antibody structure and molecular immunology. Science 
180: 830–840. Link: https://tinyurl.com/y6nxb7mc 
27. Sushma K, Vijayalakshmi MA, Krishnan V, Satheeshkumar PK (2010) Cloning, 
expression, purifi cation and characterization of a single chain variable 
fragment specifi c to tumor necrosis factor alpha in Escherichia coli. J 
Biotechnol 156: 238-244. Link: https://tinyurl.com/yxkoycss 
28. Zhu X, Wang D, Li S, Xiao Q, Tao K, et al. (2012) Expression of a humanized 
single-chain variable fragment antibody targeting chronic myeloid leukemia 
cells in Escherichia coli and its characterization. Int J Mol Med 29: 939-945. 
Link: https://tinyurl.com/y2n2ym6p 
29. Choi JH, Lee SY (2004) Secretory and extracellular production of recombinant 
proteins using Escherichia coli. Appl Microbiol Biotechnol 64: 625-635. Link: 
https://tinyurl.com/y4bd6x87 
30. Dewi KS, Retnoningrum DS, Riani C, Fuad AM (2016) Construction and 
Periplasmic Expression of the Anti-EGFRvIII ScFv Antibody Gene in 
Escherichia coli. Sci Pharm 84: 141-152. Link: https://tinyurl.com/y5xvmxvo 
31. Luckow VA, Lee SC, Barry GF, Olins PO (1993) Eﬃ  cient generation of infectious 
recombinant baculoviruses by site-specifi c transposon-mediated insertion of 
foreign genes into a baculovirus genome propagated in Escherichia coli. J 
Virol 67: 4566-4579. Link: https://tinyurl.com/y5qxckg2 
32. Furuta T, Ogawa T, Katsuda T, Fujii I, Yamaji H (2010) Eﬃ  cient production of 
an antibody Fab fragment using the baculovirus-insect cell system. J Biosci 
Bioeng 110: 577-581. Link: https://tinyurl.com/y567s48n 
33. Link: https://tinyurl.com/h73yztz 
33. Rodrigo G, Gruvegård M, Van Alstine JM (2015) Antibody Fragments and 
Their Purifi cation by Protein L Aﬃ  nity Chromatography. Antibodies 4: 259-
277. Link: https://tinyurl.com/y2o8d3bk 
34. Darcy E, Leonard P, Fitzgerald J, Danaher M, MaH, et al. (2017) Purifi cation of 
Antibodies Using Aﬃ  nity Chromatography. Methods Mol Biol 1485: 305-318. 
Link: https://tinyurl.com/y37jopw3 
35. Conroy P, Law R, Gilgunn S, Hearty S, Caradoc-Davies T, et al. (2014) 
Reconciling the structural attributes of avian antibodies. J Biol Chem 289: 
15384-15392. Link: https://tinyurl.com/y3mq2qp9
